Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease

Fassett, Robert G., Coombes, Jeff S., Packham, David, Fairley, Kenneth F. and Kincaid-Smith, Pricscilla (2010) Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scandinavian Journal of Urology and Nephrology, 44 1: 56-61. doi:10.3109/00365590903359908

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ196053.pdf HERDC Checklist - not publicly available application/pdf 48.37KB 0

Author Fassett, Robert G.
Coombes, Jeff S.
Packham, David
Fairley, Kenneth F.
Kincaid-Smith, Pricscilla
Title Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease
Journal name Scandinavian Journal of Urology and Nephrology   Check publisher's open access policy
ISSN 0036-5599
1651-2065
Publication date 2010-02
Sub-type Article (original research)
DOI 10.3109/00365590903359908
Volume 44
Issue 1
Start page 56
End page 61
Total pages 6
Editor Jan Adolfsson
Rolf Lundgren
Place of publication London, U.K.
Publisher Informa Healthcare
Collection year 2011
Language eng
Formatted abstract
Objective. Autosomal dominant polycystic kidney disease (ADPKD) is progressive, resulting in end-stage kidney failure in most patients. Experimental and clinical studies have suggested that statins may slow the progression of chronic kidney disease in general and ADPKD specifically.
Material and methods. This randomized open-label clinical trial was conducted to assess the effect of pravastatin 20 mg on kidney function and urinary protein excretion in patients with ADPKD. Sixty patients were initially recruited but 49 of these received either pravastatin 20 mg or no treatment for 2 years. Trial visits were conducted every 3 months, assessing kidney function by estimated glomerular filtration rate and 24 h urine creatinine clearance and urinary protein excretion.
Results. There were no significant (p >0.05) changes in markers of kidney function or urinary protein excretion between groups over the 2 years despite a significant fall in total serum cholesterol in pravastatin-treated patients (p 0.029).
Conclusion. This trial found that taking 20 mg pravastatin for 2 years had no significant effect on kidney function or urinary protein excretion in patients with ADPKD. The lack of statistical power limits the external validity of these findings. A larger, longer duration study using a higher dose of a more potent statin is required.
© Informa UK Ltd.
Keyword Autosomal dominant polycystic kidney disease
Chronic kidney disease
Creatinine clearance
Estimated glomerular filtration rate
Pravastatin
Proteinuria
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2011 Collection
School of Human Movement and Nutrition Sciences Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 13 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 14 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 21 Feb 2010, 00:00:47 EST